Table 2 Baseline demographic and clinical characteristics of SLE patients.
From: Risk factors for thrombotic events in Korean patients with systemic lupus erythematosus
All (N = 259) | Thrombotic events (n = 27) | No event (n = 232) | P-value | |
|---|---|---|---|---|
Age at onset of SLE, years | 34.0 ± 13.7 | 35.1 ± 14.2 | 33.9 ± 13.6 | 0.646 |
Females (%) | 239 (92.3) | 24 (88.9) | 215 (92.7) | 0.486 |
Disease duration, months | 2.87 ± 5.44 | 3.68 ± 4.79 | 2.77 ± 5.51 | 0.412 |
Ever smoker (former or current) (%) | 15 (5.8) | 3 (11.1) | 12 (5.2) | 0.196 |
Diabetes mellitus (%) | 6 (2.3) | 0 (2.7) | 6 (2.6) | 0.513 |
Hypertension (%) | 98 (37.8) | 17 (63.0) | 81 (34.9) | 0.004 |
SLEDAI-2K score | 10.7 ± 6.18 | 12.1 ± 6.53 | 10.5 ± 6.13 | 0.219 |
Met the ACR-97 criteria (%) | ||||
Malar rash | 131 (60.6) | 10 (37.0) | 121 (52.2) | 0.137 |
Discoid rash | 26 (10.0) | 1 (3.7) | 25 (10.8) | 0.214 |
Photosensitivity | 81 (31.3) | 7 (25.9) | 74 (31.9) | 0.527 |
Oral ulcer | 47 (18.1) | 2 (7.4) | 45 (19.4) | 0.096 |
Arthritis | 114 (44.0) | 10 (37.0) | 104 (44.8) | 0.440 |
Pleuritis | 31 (12.0) | 2 (7.4) | 29 (12.5) | 0.344 |
Pericarditis | 23 (8.9) | 4 (14.8) | 19 (8.2) | 0.206 |
CNS involvement | 21 (8.1) | 5 (18.5) | 16 (6.9) | 0.036 |
Renal involvement | ||||
Proteinuria | 96 (37.1) | 15 (55.6) | 81 (34.9) | 0.036 |
Hematuria | 70 (32.0) | 13 (48.1) | 70 (30.2) | 0.058 |
Pyuria | 67 (25.9) | 9 (33.3) | 58 (25.0) | 0.349 |
Hematological involvement | ||||
Lymphopenia | 201 (77.6) | 20 (74.1) | 181 (78.0) | 0.642 |
Anemia | 78 (30.1) | 9 (33.3) | 69 (29.7) | 0.700 |
Thrombocytopenia | 66 (25.5) | 8 (29.6) | 58 (25.0) | 0.601 |
Concomitant disease (%) | ||||
Interstitial lung disease | 10 (3.9) | 2 (7.4) | 8 (3.4) | 0.280 |
Raynaud’s phenomenon | 60 (23.2) | 4 (14.8) | 56 (24.1) | 0.202 |
Anti-phospholipid syndrome | 13 (5.0) | 6 (22.2) | 7 (3.0) | 0.001 |
Associated Sjögren’s syndrome | 27 (10.4) | 4 (14.8) | 23 (9.9) | 0.305 |
Thyroid disease | 20 (7.7) | 1 (3.7) | 19 (8.2) | 0.357 |
